Question

Difficulty: HardGynecologic Infections

An established 3434-year-old patient presents to the gynecology clinic reporting relentless vulvovaginal pruritus and burning that has persisted for the past month. She states that a three-dose course of oral fluconazole prescribed four weeks ago provided almost no symptom relief. Her past medical history is notable for poorly controlled type 2 diabetes mellitus with a recent hemoglobin A1c of 9.2%9.2\%. On speculum examination, the vulvar and vaginal mucosae are intensely erythematous, and there is a thick, white, clumpy discharge adherent to the vaginal sidewalls. Vaginal fluid pH is 4.24.2. Microscopic evaluation of the discharge prepared with 10%10\% potassium hydroxide reveals numerous budding yeast cells, but a complete absence of pseudohyphae or true hyphae. Which of the following is the most appropriate pharmacotherapy for this patient's condition?

  1. Intravaginal boric acidAnswer
  2. B
    Oral fluconazole, weekly for 66 months
  3. C
    Oral metronidazole
  4. D
    Topical clobetasol propionate
  5. E
    Intramuscular ceftriaxone and oral doxycycline

Answer

Intravaginal boric acid
This patient's clinical presentation of fluconazole-refractory vulvovaginitis, combined with a potassium hydroxide (10%10\% KOH) preparation demonstrating budding yeast without pseudohyphae, strongly indicates a non-albicans Candida infection. The most common culprit is Candida glabrata. Unlike Candida albicans, which is dimorphic and readily forms both budding yeast cells and pseudohyphae, Candida glabrata exists solely in the budding yeast form. Furthermore, C. glabrata is intrinsically resistant to standard azole antifungal medications (like fluconazole). Poorly controlled diabetes is a classic risk factor for these atypical, resistant fungal infections. The most appropriate first-line pharmacotherapy for symptomatic, azole-refractory C. glabrata vulvovaginitis is intravaginal boric acid (typically 600 mg600\text{ mg} daily for 1414 days).

Step-by-Step Solution

1
Analyze the patient's symptoms and medication history.
The patient has persistent vulvovaginitis that failed to improve with a standard three-dose regimen of oral fluconazole.
Treatment failure with a systemic azole raises suspicion for a non-albicans Candida species, which are inherently resistant to standard azole therapy.
2
Interpret the objective examination and laboratory findings.
Vaginal pH is normal (4.24.2), and the KOH prep shows budding yeast but strictly no pseudohyphae.
A normal pH confirms a fungal etiology (ruling out BV and Trichomonas). The strict absence of pseudohyphae differentiates Candida glabrata from Candida albicans (which typically forms both budding yeast and pseudohyphae).
3
Select the appropriate targeted pharmacotherapy.
Intravaginal boric acid is selected.
Candida glabrata is the most common non-albicans cause of vulvovaginal candidiasis and is highly resistant to fluconazole. The first-line treatment for this specific pathogen is intravaginal boric acid for 1414 days.

Key Concept

Diagnosis and management of non-albicans vulvovaginal candidiasis (Candida glabrata)
Estimated Time:1m 15s
Rate this question